Stocks›Healthcare›PTGX

PTGX

Protagonist Therapeutics, Inc

NasdaqResearch view

$141.86+3.29%

Sep 25 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsMid-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 6, 2025 and Nov 7, 2024, after the close.

Last report

Aug 5, 2026+6.45%

after the close

Last 4, next close

median 3.14% either way

up 3 of 4

Every report since 2022 →

DateEventSourceNext close

Sep 4MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?Yahoo FinanceYahoo Finance−2.07%
Aug 5Earnings release, after the close · 8-KSEC EDGARSEC EDGAR ↗+6.45%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Big days · last year

Daily closes · Databento EOD

14 big days: a close more than 4.89% from the one before, three times PTGX’s median day (1.63%). On 2 of 14, its largest peers moved the same way at least half as far. We show what we hold, never a cause.

Shaded: since our stories began, May 26, 2026

14Aug 6, 2026
Aug 6, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group −0.1% did not move with it
−0.1% did not move with itLLY +1.9 · ABBV −0.9 · JNJ −0.2 · MRK +0.0
+6.45%
13Jul 17, 2026
Jul 17, 2026Nothing in our recordNo PTGX story, brief or results filing in our record that dayGroup +0.5% did not move with it
+0.5% did not move with itJNJ +1.2 · LLY +0.8 · MRK −0.1 · ABBV +0.0
+6.73%
12Jul 7, 2026
Jul 7, 2026Nothing in our recordNo PTGX story, brief or results filing in our record that dayGroup +2.3% did not move with it
+2.3% did not move with itJNJ +3.0 · LLY +3.0 · MRK +1.6 · ABBV −0.0
+7.11%
11Jul 2, 2026
Jul 2, 2026Nothing in our recordNo PTGX story, brief or results filing in our record that dayGroup +3.5% moved the same way
+3.5% moved the same wayABBV +4.0 · JNJ +3.6 · MRK +3.3 · LLY +1.9
+5.15%
10Jun 9, 2026
Jun 9, 2026Nothing in our recordNo PTGX story, brief or results filing in our record that dayGroup +0.6% did not move with it
+0.6% did not move with itJNJ +2.1 · ABBV +1.1 · LLY −0.4 · MRK +0.1
+8.00%
9Jun 5, 2026
Jun 5, 2026Nothing in our recordNo PTGX story, brief or results filing in our record that dayGroup +0.8% did not move with it
+0.8% did not move with itJNJ +2.0 · ABBV +1.0 · LLY +0.6 · MRK +0.4
−5.26%
8Jun 4, 2026
Jun 4, 2026Nothing in our recordNo PTGX story, brief or results filing in our record that dayGroup +4.0% moved the same way
+4.0% moved the same wayMRK +4.8 · LLY +4.3 · ABBV +3.6 · JNJ +2.2
+7.74%
7May 7, 2026
May 7, 2026Before our storiesGroup −1.1% did not move with it
−1.1% did not move with itLLY −1.2 · ABBV −1.1 · MRK −1.1 · JNJ −0.9
−4.92%
6Apr 14, 2026
Apr 14, 2026Before our storiesGroup +0.4% did not move with it
+0.4% did not move with itABBV +1.8 · JNJ +0.9 · LLY −0.8 · MRK −0.2
+7.33%
5Apr 10, 2026
Apr 10, 2026Before our storiesGroup −1.4% did not move with it
−1.4% did not move with itABBV −2.1 · LLY −1.6 · JNJ −1.2 · MRK −1.0
−5.06%
4Mar 31, 2026
Mar 31, 2026Before our storiesGroup +1.9% did not move with it
+1.9% did not move with itLLY +3.7 · ABBV +2.0 · MRK +1.9 · JNJ +0.8
+5.54%
3Mar 9, 2026
Mar 9, 2026Before our storiesGroup +1.0% did not move with it
+1.0% did not move with itLLY +1.8 · ABBV −1.2 · MRK +1.1 · JNJ +0.9
+4.96%
2Oct 13, 2025
Oct 13, 2025Before our storiesGroup −0.2% did not move with it
−0.2% did not move with itLLY −1.7 · MRK −0.3 · JNJ +0.1 · ABBV −0.1
−9.00%
1Oct 10, 2025
Oct 10, 2025Before our storiesGroup −1.0% did not move with it
−1.0% did not move with itLLY −2.6 · MRK −1.7 · JNJ −0.2 · ABBV −0.1
+29.77%

A story on the same day is not a cause, and a group move is not proof either. Group: LLY, JNJ, ABBV, MRK, the largest companies in PTGX’s SEC industry; “the same way” means the same direction and at least half as far. Prior-session closes only; not a call, not advice.

The numbers · FY2025, filed

SEC EDGAR

Market cap$9.2B

Revenue$46.0M−89.40%

Net income$-130.1M

EPS, diluted$-2.05−148.50%

Operating margin-343.6%

Return on equity-21.2%

Debt / equity0.02

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$9.2B

Enterprise Value$9.1B

Income$-130.1M

Sales$46.0M

Book/sh$9.50

Cash/sh$1.99

Dividend TTM—

Payout—

Employees—

IPO—

Quick Ratio—

Current Ratio12.71

Debt/Eq0.02

EPS (ttm)$-2.05

EPS this Y-148.5%

EPS past 3/5Y—

Sales past 3/5Y20.1%

EPS Y/Y TTM-148.5%

Sales Y/Y TTM-89.4%

Shs Outstand64.71M

ROA-19.5%

ROE-21.2%

ROIC-32.1%

Gross Margin—

Oper. Margin-343.6%

Profit Margin-282.8%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$27.4M

FY21

$26.6M

FY22

$60.0M

FY23

$434.4M

FY24

$46.0M

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$27.4M	$26.6M	$60.0M	$434.4M	$46.0M
Gross Profit	—	—	—	—	—
Operating Income	$-125.8M	$-131.4M	$-93.7M	$252.8M	$-158.1M
Net Income	$-125.6M	$-127.4M	$-79.0M	$275.2M	$-130.1M
Diluted EPS	$-2.71	$-2.60	$-1.39	$4.23	$-2.05
Operating Cash Flow	$-107.9M	$-108.1M	$-70.2M	$184.2M	$57.7M
Free Cash Flow	$-109.0M	$-108.9M	$-70.8M	$182.8M	$56.1M

Same industry

In the screener →

LLY$1.11T JNJ$653.6B ABBV$467.1B MRK$367.1B ABT$175.3B PFE$163.4B VRTX$133.4B BMY$128.4B

Follow the news. Track the move.

PTGX story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

PTGX direct/Earnings

Sep 4

MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?

MIMRYLO approval triggered $275M in payments for Protagonist Therapeutics, putting royalties at the center of the company’s commercial model. The setup is financially significant but difficult to underwrite directionally from the available disclosure because PTGX’s latest reported revenue fell 89.4% year over year and the company remained deeply loss-making.

Since story

-2.6%

2026-09-04 → 2026-09-25

Yahoo Finance · 22d ago

View both sides →

Follow the news. Track the move.